Eli Lilly and Company (NYSE:LLY) Shares Gap Up on Earnings Beat

Eli Lilly and Company (NYSE:LLY) gapped up prior to trading on Wednesday following a stronger than expected earnings report. The stock had previously closed at $1,003.46, but opened at $1,075.12. Eli Lilly and Company shares last traded at $1,081.8480, with a volume of 1,494,382 shares.

The company reported $7.54 earnings per share for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.32 earnings per share.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q4 results beat expectations: adjusted EPS and revenue well above consensus, driven by volume growth. Eli Lilly sees 2026 profit above estimates on weight‑loss drug demand
• Positive Sentiment: Management issued 2026 guidance above Street estimates (revenue and profit outlook), signaling confidence in continued GLP‑1 growth. Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar
• Positive Sentiment: Blockbuster drug momentum: Mounjaro and Zepbound sales doubled/grew triple digits in Q4 — primary driver of the beat and future cash flow expectations. Eli Lilly (LLY) Stock: Strong Earnings Beat Sends Shares Soaring on Weight-Loss Drug Growth
• Positive Sentiment: Capacity & pipeline investments: a $3.5B injectable manufacturing site and partnerships/biotech deals expand long‑term production and R&D optionality. Eli Lilly plans $3.5B injectable manufacturing site in Pennsylvania
• Neutral Sentiment: Strategic M&A/partnerships (Seamless Therapeutics, Veradermics, Zonsen) diversify pipeline beyond GLP‑1s — positive long term but not immediate EPS drivers. Eli Lilly Is Getting Into the Hearing Loss Market in a $1.12 Billion Deal With Seamless Therapeutics
• Neutral Sentiment: Analysts noted rising R&D and capacity spending could compress near‑term margins despite top‑line strength — monitor guidance vs. actual margins. Eli Lilly Q4 Preview: Wall St Sees Revenue Beat On Weight-Loss Heft But R&D Costs Could Drag Profits
• Negative Sentiment: Competitive and pricing pressures: Novo Nordisk’s warning and aggressive Wegovy pill launch have hammered sector sentiment and raised concerns about future pricing and share dynamics. Novo Nordisk (NVO) Stock: CEO’s Warning Sends Shares Into Freefall
• Negative Sentiment: U.S. pricing pressure (policy and payer negotiations) remains a material risk that could limit margin upside even as volumes grow. Eli Lilly Profit Rises as Weight-Loss Drug Demand Surges

Analyst Ratings Changes

LLY has been the subject of a number of recent research reports. Wolfe Research boosted their target price on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research report on Wednesday, December 3rd. Leerink Partners set a $1,234.00 target price on Eli Lilly and Company in a report on Monday, January 5th. Daiwa Capital Markets set a $1,230.00 price objective on Eli Lilly and Company and gave the company a “buy” rating in a report on Tuesday, December 16th. TD Cowen boosted their price objective on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. Finally, Deutsche Bank Aktiengesellschaft raised their price objective on Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,162.75.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in LLY. Laurel Wealth Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after buying an additional 11,537,661 shares in the last quarter. Norges Bank acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at about $8,827,714,000. Capital Research Global Investors grew its holdings in Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after buying an additional 4,332,008 shares during the last quarter. Vanguard Group Inc. grew its stake in Eli Lilly and Company by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after acquiring an additional 1,183,038 shares during the period. Finally, Amundi grew its stake in shares of Eli Lilly and Company by 27.1% during the 3rd quarter. Amundi now owns 4,525,902 shares of the company’s stock valued at $3,823,977,000 after buying an additional 964,675 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 7.6%

The firm has a 50-day moving average of $1,054.28 and a 200 day moving average of $893.81. The stock has a market capitalization of $1.02 trillion, a price-to-earnings ratio of 52.69, a price-to-earnings-growth ratio of 0.79 and a beta of 0.39. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.